T 0147/22 (TAS-102 formulation/TAIHO) of 18.01.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T014722.20240118
- Date of decision
- 18 January 2024
- Case number
- T 0147/22
- Online on
- 3 May 2024
- Petition for review of
- -
- Application number
- 13749171.8
- IPC class
- A61P 43/00A61K 31/7072A61K 47/32A61K 47/26A61K 47/10A61P 35/00A61K 9/20A61K 47/38A61K 31/513A61K 9/28A61K 47/36
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 084
- Application title
- ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION
- Applicant name
- Taiho Pharmaceutical Co., Ltd.
- Opponent name
- Teva Pharmaceutical Industries Ltd
- Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1) 1973European Patent Convention Art 123(2) 1973European Patent Convention Art 56 1973European Patent Convention Art 84 1973Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(4)
- Keywords
- Substantial procedural violation - (no)
Remittal - (no)
Amended claims - admitted (yes) - clarity (yes) - added subject-matter (no)
Inventive step - (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form on the basis of the main request, filed as auxiliary request 4 with the statement setting out the grounds of appeal, and, if necessary, a description to be adapted thereto.